A biotechnology company in bankruptcy has brought malpractice claims against Nixon Peabody and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo.
In a suit filed Tuesday in the Eastern District, Neogenix Oncology Inc. said that at the direction of its former CFO, Peter Gordon, it paid commissions for sales of company stock, regardless of whether the “finders” were licensed to sell securities. The suit said the fee program violated securities laws because it compensated unlicensed finders based on their successful brokering the sale of stock.
